India has long been known as the "pharmacy of the world" because it produces affordable medicines and vaccines. However, when it comes to developing new drugs, especially antibiotics, the country has been largely absent from the spotlight. But that is about to change with Nafithromycin, a breakthrough drug that could transform global healthcare. Expected to be available by 2025 under the brand name Miqnaf, Nafithromycin is India's first ever indigenously developed antibiotic to fight resistant infections.
A Timely Solution to a Growing Crisis
Nafithromycin isn't just any ordinary antibiotic—it's specifically designed to tackle drug-resistant pneumonia, one of the deadliest diseases globally. Antibiotic resistance (AMR) is quickly becoming a major public health threat. According to experts, AMR could cause up to 10 million deaths annually by 2050 if not addressed. This problem is even worse in low-income countries like India, where pneumonia kills thousands every year. In fac...
Full Access
Included:
-
Access to All Articles.
-
One Plan. No Tiers.
-
No Ads.
-
Cancel anytime.
